秒速飞艇正规平台

Please Join Us for An Interactive Virtual Town Hall Presentation!

About

秒速飞艇正规平台The role of GLP-1 receptor agonists in the management of Type 2 diabetes is continually evolving, challenging pharmacists to stay current with the latest science.

This unique question-driven presentation will provide learners the opportunity to interact with expert faculty in real time. Please submit your questions at the time of event registration. Questions will be answered during the Virtual Town Hall.

Dates/Times:

Faculty

Joshua J. Neumiller, PharmD, CDCES, FASCP, FADCES
Vice Chair & Allen I. White Distinguished Associate Professor, Pharmacotherapy
Washington State University
秒速飞艇正规平台 Spokane, WA

Jennifer Trujillo, PharmD, FCCP, BCPS, CDCES, BC-ADM
Professor, Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Aurora, CO
Clinical Pharmacist and Certified Diabetes Care and Education Specialist
UCHealth Diabetes and Endocrinology Clinic
Anschutz Medical Campus
秒速飞艇正规平台 Aurora, CO

Heather P. Whitley, PharmD, BCPS, CDCES
Clinical Professor, Pharmacy Practice
Auburn University Harrison School of Pharmacy
Auburn, AL
Clinical Pharmacy Specialists
Baptist Family Medicine, Baptist Health System
Montgomery, AL

Goal
秒速飞艇正规平台To inform and educate pharmacists on the most up-to-date information on the use of GLP-1 RAs in patients with T2D, including in-depth discussions of new agents, review and application of current clinical practice recommendations, review of data on cardiovascular outcomes, and practical discussions regarding patient management. This educational initiative will provide learners with the knowledge and competence to improve the care and outcomes of patients with T2D.

Learning Objectives
秒速飞艇正规平台Upon completion of this program, participants should be better able to:

Explain秒速飞艇正规平台 Explain the rationale for guideline recommendations on use of GLP-1 receptor agonists in patients with type 2 diabetes

Compare 秒速飞艇正规平台dosing, administration, clinical effects and tolerability of currently available GLP-1 receptor agonists

Discuss秒速飞艇正规平台 recent cardiovascular outcome trial (CVOT) findings with GLP-1 receptor agonists and implications in clinical practice

UAN: 0430-0000-20-101-L01-P
Credits: 1.25 hour (0.125 ceu)
Duration: 75 minutes
Location: From the convenience of your home or business; accessible via both PC and MAC
Fee: There is no fee for this educational activity
Target Audience: Pharmacists
Type of Activity: Application

Agenda

Introduction (5 minutes)
Presentation (60 minutes)
Conclusions & Question & Answer Session (10 minutes)
How to Earn Credit
Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.

Required Computer Hardware/Software
秒速飞艇正规平台Please ensure the computer system you plan to use meets the following minimum requirements:

Operating System:秒速飞艇正规平台 Windows 98 or higher & Macintosh 2.2 or higher

Internet Browser (Mac &/ Windows):秒速飞艇正规平台 Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher

Broadband Internet connection:秒速飞艇正规平台 Cable, High-speed DSL & any other medium that is internet accessible

Peripherals:秒速飞艇正规平台 Computer speakers or headphones

Monitor Screen Resolution:秒速飞艇正规平台 320 x 480 or higher

Media Viewing Requirements:秒速飞艇正规平台 Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Accreditation Statements
Pharmacy:秒速飞艇正规平台 Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Novo Nordisk, Inc.